Oramed Pharmaceuticals Inc. (ORMP): Price and Financial Metrics


Oramed Pharmaceuticals Inc. (ORMP)

Today's Latest Price: $2.86 USD

0.11 (4.00%)

Updated Sep 25 4:00pm

Add ORMP to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

ORMP Stock Summary

  • Oramed Pharmaceuticals Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 11.94% of US listed stocks.
  • For ORMP, its debt to operating expenses ratio is greater than that reported by merely 4.51% of US equities we're observing.
  • ORMP's price/sales ratio is 24.83; that's higher than the P/S ratio of 93.63% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Oramed Pharmaceuticals Inc are CRIS, MGEN, ARCT, GSIT, and EIDX.
  • Visit ORMP's SEC page to see the company's official filings. To visit the company's web site, go to www.oramed.com.
ORMP Daily Price Range
ORMP 52-Week Price Range

ORMP Stock Price Chart Technical Analysis Charts


ORMP Price/Volume Stats

Current price $2.86 52-week high $6.05
Prev. close $2.76 52-week low $2.32
Day low $2.72 Volume 79,896
Day high $2.87 Avg. volume 131,494
50-day MA $3.52 Dividend yield N/A
200-day MA $3.86 Market Cap 67.29M

Oramed Pharmaceuticals Inc. (ORMP) Company Bio


Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. The company was founded in 2002 and is based in Jerusalem, Israel.


ORMP Latest News Stream


Event/Time News Detail
Loading, please wait...

ORMP Latest Social Stream


Loading social stream, please wait...

View Full ORMP Social Stream

Latest ORMP News From Around the Web

Below are the latest news stories about Oramed Pharmaceuticals Inc that investors may wish to consider to help them evaluate ORMP as an investment opportunity.

ORMP: Advancing Toward Phase 3 Program For ORMD-0801

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), a clinical-stage pharmaceutical company with a proprietary oral protein delivery platform technology, is getting ready to initiate two Phase 3 clinical trials after the FDA has reviewed its Phase 3 protocols and nonclinical documents. This follows positive feedback from the FDA during its end of

Yahoo | September 22, 2020

Oramed Pharmaceuticals to Present at the European Association for the Study of Diabetes (EASD) Annual Meeting

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced it will present at the EASD Annual Meeting, held virtually this year, September 21-25, 2020.

Yahoo | September 21, 2020

Oramed's Diabetes Market Survey Shows Strong Support for ORMD-0801 Oral Insulin Among Physicians and Patients

NEW YORK , Sept. 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced results from a diabetes market survey conducted for Oramed by a third party research firm. The survey included qualitative interviews with healthcare providers as well as type 1 (T1D) and type 2 (T2D) diabetes patients regarding Oramed's lead oral insulin product, ORMD-0801, which is headed into a Phase III trial. Forty-one health care providers, including 22 endocrinologists and 19 primary care physicians, nurse practitioners, physician assistants and certified diabetes educators were surveyed. There was strong support among these health care providers for ...

Benzinga | September 15, 2020

Company News for Jul 16, 2020

Companies in the new are: INFY, PGR, BE, ORMP

Yahoo | July 16, 2020

Oramed Reports Positive End of Phase 2 Meeting With the FDA for Oral Insulin

NEW YORK , July 15, 2020 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801). Based on the FDA's feedback, Oramed intends to initiate two Phase 3 clinical trials following FDA review of those Phase 3 protocols, and nonclinical documents. The FDA outlined its expectations for design of the ORMD-0801 Phase 3 trials as well as submission of the Biologics License Application (BLA) that would follow successful trials. Oramed plans to conduct the two Phase 3 trials concurrently. Oramed's Chief Executive Nadav Kidr...

Benzinga Feeds | July 15, 2020

Read More 'ORMP' Stories Here

ORMP Price Returns

1-mo -17.34%
3-mo -18.05%
6-mo -5.92%
1-year -7.74%
3-year -71.99%
5-year -48.75%
YTD -44.47%
2019 71.67%
2018 -66.67%
2017 47.06%
2016 -28.42%
2015 87.50%

Continue Researching ORMP

Want to see what other sources are saying about Oramed Pharmaceuticals Inc's financials and stock price? Try the links below:

Oramed Pharmaceuticals Inc (ORMP) Stock Price | Nasdaq
Oramed Pharmaceuticals Inc (ORMP) Stock Quote, History and News - Yahoo Finance
Oramed Pharmaceuticals Inc (ORMP) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7495 seconds.